Solana Company Reports $2.5 Million Q2 Revenue as Digital Asset Treasury Pivot Builds Operating Infrastructure

Solana Company (NASDAQ: HSDT), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to the Solana ecosystem, reported second quarter 2026 results on August 14, 2026. The company generated $2.5 million in revenue, nearly all from staking rewards on its SOL holdings, up sharply from $43,000 a year earlier but 13.8% below Wall Street’s $2.9 million estimate. Net loss widened to $30.3 million, or $0.38 per basic and diluted share, driven primarily by a $25.4 million realized loss from actual SOL sales and $11.1 million in general and administrative expenses. Shares closed regular trading down 5.6% at $1.70 ahead of the release.

A Medical Device Company Rebuilt as Solana Infrastructure

Solana Company’s current business bears little resemblance to what it was a year ago. The company operated as Helius Medical Technologies, a neurotech firm marketing the Portable Neuromodulation Stimulator for neurologic deficits, until a series of transactions beginning in September 2025 redirected its entire capital structure toward Solana. Backed by more than $500 million in financing led by Pantera Capital and Summer Capital, the company accumulated SOL as its primary treasury asset, formally changed its name to Solana Company, and entered a letter of intent with the Solana Foundation. In Q2 2026, the pivot moved from treasury accumulation toward operating infrastructure: the company completed divestiture of its legacy medical device business and built its first institutional validator cluster in Tokyo under its Pacific Backbone initiative, marking a shift from simply holding SOL toward generating revenue from staking and institutional services.

Staking Revenue Outperforms the Network, But Realized Losses Dominate the P&L

The operating results reflect a business still early in its buildout. Staking rewards contributed $2.5 million in Q2 at a 6.14% annualized yield, beating the Solana network average by 46 basis points—a meaningful outperformance for a company positioning itself as an institutional-grade staking provider. Gross margin on that revenue reached approximately 97%. Set against that, general and administrative expenses jumped to $11.1 million from $3.3 million a year earlier, including $6.8 million in severance costs tied to the medical device divestiture. The $30.3 million net loss was driven primarily by the $25.4 million realized loss recognized on actual SOL sales during the quarter, combined with the elevated G&A spend; the unrealized, non-cash fair value line on digital assets was actually a $2.4 million gain in Q2, which partially offset rather than added to the loss. SOL holdings declined approximately 12% during the quarter, following a 33% decline in Q1, reflecting both strategic sales and broader digital asset price volatility rather than operational underperformance.

Balance Sheet Actions and an Unsolicited Proposal Frame the Path Forward

Solana Company ended Q2 with $3.6 million in cash and total assets of $176.1 million, the majority held in current and long-term digital assets and related exposure. The company raised $7.9 million through a registered direct offering during the quarter and repurchased 1.3 million shares for approximately $2.3 million, bringing year-to-date buybacks to roughly $5.9 million. Management also secured its first third-party staking commitment, approximately $0.5 million, expected to generate revenue starting in Q3 2026, and formed partnerships with the JITO Foundation and Alatau City to extend its institutional infrastructure and policy engagement across Asia-Pacific. Separately, the board unanimously rejected an unsolicited proposal from Forward Industries in June 2026, signaling management’s intent to pursue its current strategy independently rather than entertain external combination offers.

Strategic Investment Summary

• Q2 2026 Revenue: Solana Company (NASDAQ: HSDT) reported Q2 revenue of $2.5 million, almost entirely from SOL staking, up from $43,000 a year earlier but missing the $2.9 million consensus estimate by 13.8%.
• Net Loss Driven by Non-Cash Items: Net loss widened to $30.3 million ($0.38 per share), driven primarily by a $25.4 million realized loss on actual SOL sales and $11.1 million in G&A expenses; the unrealized fair value mark on digital assets was actually a $2.4 million gain, partially offsetting the loss. SOL holdings fell approximately 12% in Q2 after a 33% decline in Q1.
• Staking Yield Outperformance: Staking rewards generated a 6.14% annualized yield, beating the Solana network average by 46 basis points, with approximately 97% gross margin on staking revenue.
• Infrastructure Buildout: The company completed its first institutional validator cluster in Tokyo under the Pacific Backbone initiative, secured its first third-party staking commitment of approximately $0.5 million expected to generate Q3 revenue, and divested its legacy medical device business.
• Balance Sheet Activity: Solana Company held $3.6 million in cash and $176.1 million in total assets at June 30, 2026, raised $7.9 million via a registered direct offering in Q2, and repurchased approximately $5.9 million in shares year-to-date.
• Rejected Proposal: The board unanimously rejected an unsolicited proposal from Forward Industries in June 2026, and elevated G&A expenses of $11.1 million included $6.8 million in severance costs tied to the medical device divestiture.

Find out more about the latest corporate developments and financial reports at the Solana Company investor portal.